** Jade Biosciences' JBIO.O shares down 6.2% after hours to $16.50 as it looks to raise equity

** Autoimmune diseases-focused biotech announces offering comprised of stock and pre-funded warrants; deal size not disclosed

** Jefferies, TD Cowen and UBS joint bookrunners

** Co intends to use net offering proceeds to fund clinical trials, preclinical studies, R&D, and for capex, among other purposes

** With ~49.4 mln shares outstanding, co has about $870 mln market cap

** JBIO stock ended Weds down 0.9% at $17.59, up 14% YTD

** 6 analysts rate the stock "strong buy", the other 4 "buy"; median PT of $43.50 up from $24.50 a month ago, according to LSEG data